Capital World Investors Prothena Corp Public LTD CO Transaction History

Capital World Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $1.67 Million - $6.72 Million	-152,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$27.95 - $45.04 $28.4 Million - $45.8 Million	-1,016,214 Reduced 86.99%	152,000 $5.58 Million
Q4 2017 Feb 14, 2018	SELL	$35.44 - $63.76 $5.49 Million - $9.88 Million	-154,900 Reduced 11.71%	1,168,214 $43.8 Million
Q3 2017 Nov 14, 2017	BUY	$53.83 - $67.75 $71.2 Million - $89.6 Million	1,323,114	1,323,114 $85.7 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $678M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.